Melbourne healthtech Everlab has closed an oversubscribed $65 million AUD Series A to attack a simple premise: most of medicine is built to treat people once they're already sick, and the bigger opportunity is catching problems first.

Airtree Ventures led the round, with Plural and returning backers Left Lane Capital and b2venture, plus angels including Australian Test captain Pat Cummins. It follows a $15 million seed round less than a year ago.

Everlab's app stitches together diagnostics, doctors, specialists, prescriptions, and continuous AI-assisted care into a single longitudinal view, integrating 1,850 provider locations, 180 clinicians, and 30 wearables, while processing 200,000 health reports monthly. It has completed 40,000 consultations across 20,000 patients and processed 21 million biomarker results — flagging undetected findings in more than 25% of members.

That track record has pulled in corporate clients including BCG, BHP and Bain, where CEO Marc Hermann says prevention is shifting from a wellbeing perk to a "performance, productivity and risk-management initiative."

The cash funds a push into the UK and the $10 trillion global consumer healthcare market.